Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 02:00PM GMT
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

We have Amicus Therapeutics here with us today. With us from Amicus is John Crowley, Chairman and CEO. Thank you so much for joining us at the UBS Healthcare Conference.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

And maybe just to kick it off, John, just for some background, those who are newer to the story. Can you give us a quick overview of Amicus' rare disease portfolio and, I guess, key goals for the company in the coming years?

John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO

Great. Of course, Ellie. Thank you, and thank you for having me. I apologize I have to join by telephone here. I guess I didn't have the latest version of Google Chrome updated. But thank you, everybody, for listening.

To remind everybody, Amicus is a global biotechnology company, and we focus in the rare diseases, and we have since the founding of the company. We have a range of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot